Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Negocios · 23/7/20261 min de lectura
Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
Traducción automática local · Idioma original de la fuente
Resumen
The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Modala Bio, Inc. (Modala), headquartered in Delaware.
Idioma original de la fuente: Federal Register — Health and Human ServicesAbrir el comunicado original →